This is a purified rabbit anti-human ADAM Monoclonal Antibody, Recombinant, that can be used in the validated applications of Western blot, ELISA, flow cytometry and immunohistochemistry. This ADAM Monoclonal Antibody was obtained from a rabbit immunized with purified, human cell-derived, recombinant human ADAM.
Antibody characteristics include:
Applications: This ADAM Monoclonal Antibody, Recombinant, has been validated for use in Western blot, ELISA, flow cytometry and immunohistochemistry
Host species and isotype: This is a rabbit Monoclonal IgG against human ADAM
Clone ID of monoclonal antibody (mAb): The ADAM monoclonal antibody clone ID is 007
Immunogen: Recombinant human ADAM protein
Product size: 100 µg
As described by NCBI, The adamalysin (ADAM) metalloproteinase disintegrins, also known as metalloprotease / disintegrin/cysteine-rich proteins, are a branch of the metzincin metalloproteinase superfamily that are related to snake venom metalloproteinases and integrin ligands. human ADAM15 was first named metargidin, and uniquely, it carries an RGD binding motif in a position similar to that in snake venom disintegrins. ADAM15 is widely expressed in various tissues and cells, including human umbilical vein endothelial cells and smooth muscle cells, and its expression can be drived by Vascular endothelial (VE)-cadherin. Overexpression of ADAM15 in NIH3T3 cells appears to enhance cell-cell interactions, as suggested by decreased cell migration, altered cell morphology at the wound edge, decreased monolayer permeability, and increased cell adhesion to monolayers of cells expressing ADAM15 by retroviral transduction. ADAM15 plays a physiological role as a natural binding partner of integrin αvβ3 thereby loosening tumor cell adhesion to the underlying matrix and regulating tumor cell migration and invasion, and functional interplay between ADAM15 and Src family PTKs may contribute to signaling in hematopoietic cells. Aslo, ADAM15 is believed to interact with integrins αvβ3, α5β1, and α9β1 through its disintegrin domain. ADAM15 has been shown to degrade collagens I and IV and to cleave the inflammatory cytokine CD23, thus influence ECM remodeling within rheumatoid synovial tissues and in atherosclerosis.